About Immunai
Immunai is a precision medicine company that leverages artificial intelligence and single-cell multiomics to decode the immune system and accelerate therapeutic development. The company has built AMICA, the world's largest immune-focused, harmonized single-cell database, comprising data from over 5,000 studies, 350+ single-cell studies, 800+ cell types, and 300,000+ patient samples. Immunai's integrated end-to-end platform combines high-quality multiomic data generation, advanced machine learning through their ImmunoDynamics Engine (IDE), and functional genomics validation to deliver actionable insights for drug discovery and development. The company offers three core solutions: Target Discovery to identify novel high-impact targets linked to disease, Preclinical Evaluation to prioritize promising drug candidates, and Clinical Trial Optimization to identify patient subgroups and treatment strategies that maximize trial success. Immunai partners with leading biopharmaceutical companies including AstraZeneca and Teva on projects ranging from inflammatory bowel disease target discovery to vitiligo disease mechanism research and oncology clinical trial optimization. The company's multidisciplinary team combines expertise in immunology, computational biology, machine learning, and drug development to transform complex therapeutic questions into clear, data-driven recommendations that help pharma companies make smarter choices, reduce risks, and bring better therapies to patients faster.
Mission & Story
Mission
We are mapping the immune system at unprecedented scale & resolution to facilitate development of next-generation immune-related therapeutics
Clinical Focus
Medical conditions and clinical areas addressed by Immunai.
Who It Serves
Milestones & Awards
Recent Milestones
May 2026: AstraZeneca expanded AI oncology collaboration; October 2025: Agreement with AstraZeneca to advance IBD target; April 2025: Partnership with Parker Institute to build massive cancer single-cell dataset; March 2025: Appointed former Pfizer CSO Mikael Dolsten to Board; November 2024: Collaboration with Teva for oncology and immunology trials; September 2024: Collaboration with AstraZeneca for clinical trial optimization
Key Partnerships
Social & Media
Latest Updates
Immunai announces collaboration with AstraZeneca for advanced clinical trial optimization
AstraZeneca expands AI oncology collaboration with Immunai
Immunai Appoints Former Pfizer CSO and R&D Chief, Mikael Dolsten to Board of Directors
Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology
Immunai and Parker Institute to Build Massive Cancer Single-Cell Dataset
Company Details
- Headquarters
- New York, NY, USA
- Employees
- 51-200
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.